These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26872236)

  • 1. [Non-adherence to biological therapy in patients with rheumatic diseases in the Brazilian Unified National Health System in Minas Gerais State, Brazil].
    Dabés CG; Almeida AM; Acurcio Fde A
    Cad Saude Publica; 2015 Dec; 31(12):2599-609. PubMed ID: 26872236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions.
    Calip GS; Adimadhyam S; Xing S; Rincon JC; Lee WJ; Anguiano RH
    Semin Arthritis Rheum; 2017 Oct; 47(2):157-164. PubMed ID: 28410817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients.
    Chu LH; Kawatkar AA; Gabriel SE
    Clin Ther; 2015 Mar; 37(3):660-666.e8. PubMed ID: 25618317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations.
    da Silva MRR; Dos Santos JBR; Almeida AM; Guerra Júnior AA; Alvares Teodoro J; Acurcio FA
    Expert Rev Clin Immunol; 2019 Aug; 15(8):879-887. PubMed ID: 31192746
    [No Abstract]   [Full Text] [Related]  

  • 5. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis.
    Santoleri F; Sorice P; Lasala R; Rizzo RC; Costantini A
    J Med Econ; 2014 May; 17(5):320-5. PubMed ID: 24641160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
    Li P; Blum MA; Von Feldt J; Hennessy S; Doshi JA
    Value Health; 2010; 13(6):805-12. PubMed ID: 21054657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.
    Vogelzang EH; Hebing RCF; Nurmohamed MT; van Kuijk AWR; Kruijff JWF; l'Ami MJ; Krieckaert CLM; Wolbink G
    PLoS One; 2018; 13(10):e0205125. PubMed ID: 30300358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
    J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis.
    Santoleri F; Romagnoli A; Costantini A
    Expert Opin Drug Saf; 2020 Jan; 19(1):93-97. PubMed ID: 31615274
    [No Abstract]   [Full Text] [Related]  

  • 18. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
    Dalén J; Svedbom A; Black CM; Kachroo S
    Rheumatol Int; 2017 Dec; 37(12):2049-2058. PubMed ID: 28975392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
    Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
    Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.